Kengo Nagashima

77PUBLICATIONS
201CO-AUTHORS
Predictive and prognostic markersCancer therapy (excl. chemotherapy and radiation therapy)Behavioural epidemiologyMolecular targetsSocial epidemiology
Featured researcher

Get your video featured.

JoVEPublish with JoVE
Journal

Publications (77)

|Aug 08, 2026
Monitoring with plasma apolipoprotein A2-isoforms can predict developing new-onset steatotic liver disease caused by pancreatic exocrine insufficiency following pancreatectomy.

|Jul 06, 2026
Association of the PD-L1 CPS With the Efficacy of First-Line Nivolumab Plus Chemotherapy for Unresectable Advanced or Recurrent Gastric Cancer.

|Mar 28, 2026
A Pancreatic Ductal Adenocarcinoma Diagnostic System Using Serum Extracellular Vesicle Detection with Optimized Lectin Combination Using Machine Learning.

Tatsuya Kawakami, Sho Uemura, Masayuki Ono

|Mar 16, 2026
Association between modifiable lifestyle factors and the incidences of sudden sensorineural hearing loss and Meniere's disease: A population-based nested case-control study.

Misuzu Fujita, Kengo Nagashima, Yoshihiro Onouchi

|Feb 17, 2026
Survival after pathological complete response following neoadjuvant chemotherapy versus chemoradiotherapy for oesophageal squamous cell carcinoma.

Jun Okui, Satoru Matsuda, Kengo Nagashima

|Feb 02, 2026
ANGPTL3 in the Peripheral Circulation Is Associated with Resistance to Anti-PD1 Therapy in Advanced Gastric Cancer.

Chie Kudo-Saito, Hirokazu Shoji, Kengo Nagashima

Pageof 13

Frequent Collaborators

10 joint publications

Misuzu Fujita

6 joint publications

Jun Okui

6 joint publications

Satoru Matsuda

5 joint publications

Hisashi Noma